FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
SHERMAN STEVEN
   2. Issuer Name and Ticker or Trading Symbol
EKSO BIONICS HOLDINGS, INC. [EKSO] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO & Chairman
(Last)
(First)
(Middle)
C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY S, STE. 1201		 3. Date of Earliest Transaction (Month/Day/Year)
06/10/2021
(Street)

RICHMOND, CA 94804		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1) 06/10/2021(2)   A   18,265 A $ 0 655,673 D  
Common Stock 06/15/2022   S   6,911 (3) D $ 1.8982 (4) 648,762 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
SHERMAN STEVEN
C/O EKSO BIONICS HOLDINGS, INC.
1414 HARBOUR WAY S, STE. 1201
RICHMOND, CA 94804		   X     CEO & Chairman  

Signatures

 /s/ Jerome Wong, as Attorney-in-Fact   06/17/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents restricted stock units ("RSUs"). Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting.
(2) This award of RSUs was granted effective June 10, 2021, the date of the Company's 2021 annual meeting of stockholders (the "First Grant Date"), pursuant to an automatic annual non-employee director grant provision approved by the Company's Board of Directors on April 13, 2021 (the "Annual RSU Grant Program"). The RSUs were scheduled to vest and settle at the earlier of the date of the next annual meeting of stockholders or the one-year anniversary of the First Grant Date, and accordingly fully vested on June 9, 2022, the date of the Company's 2022 annual meeting of stockholders.
(3) Represents shares sold by the Reporting Person on June 15, 2022 to cover tax withholding obligations incurred upon the vesting and settlement of the Reporting Person's RSUs.
(4) The sale price represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $1.88 to $1.94, inclusive. The Company can provide the full information regarding the number of shares sold at each separate price upon further request.
 
Remarks:
This Form 4 is being filed late due to inadvertent administrative error.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.